Entheon Biomedical

Psychedelics biotech startup Entheon Biomedical (CSE: ENBI) (OTCQB: ENTBF) announced the approval by the local Dutch ethics committee for a Phase 1 clinical trial evaluating the pharmacokinetics, pharmacodynamics and safety profile of the psychedelic compound DMT. DMT is known as the active...

Image provided by Flickr The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga. A growing body of research indicates that psychedelics are safe and potentially effective as treatments for a...

Psychedelics biotech company Entheon Biomedical Corp. (CSE: ENBI) has purchased biotech company HaluGen Life Sciences Inc. in an all-stock transaction. Entheon acquired 100% of HaluGen in exchange for 5.1 million Entheon shares. Why Genetic Testing Is Important: Psychedelic compounds...

This article was originally published on Microdose Psychedelic Insights and appears here with permission. The mantra of the emerging psychedelic medicine industry ought to be collaboration over competition. It seems that almost every week, a new collaboration or partnership is...

Canada Allows Professionals In Training To Use Psilocybin The Canadian Health Minister Patty Hajdu has allowed 17 healthcare professionals to possess and use psilocybin to conduct professional training in psilocybin-assisted therapy. The decision, announced Tuesday, marks the latest step in Canada...

Clinical trials on the hallucinogenic drug DMT for the treatment of depression are expected to start in January. According to The Guardian, the UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) gave the green light to the Imperial College of London, in partnership with...

Oregon has become the first state in US history to set up a program that regulates psilocybin, the active psychedelic ingredient in “magic mushrooms.”  Measure 109 was approved by 55.8% of voters in a ballot vote on Election Day. The measure creates a state-licensed psilocybin-...

The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga. Psychedelics is an emerging industry with a lot of potential in the way of drug development and therapy. For many years, psychedelics have...

Since the first psychedelic companies went public in March, an array of other psychedelic start-ups followed along in a trend that can now be safely referred to as the "Psychedelic Rush." In the last two months, at least five different psychedelics companies announced plans to go public...

Among the biggest challenges faced by the psychedelics industry is the stigma that surrounds it. "The anti-drug marketing of the past decades was highly effective, and so now when psychedelics are mentioned, visions of tie-dye come to mind," Timothy Ko told Benzinga.  The times...